Royce & Associates’s Bio-Techne TECH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$39.7M Buy
759,712
+81,210
+12% +$4.87M 0.39% 59
2025
Q4
$39.9M Buy
678,502
+18,468
+3% +$1.12M 0.4% 58
2025
Q3
$36.7M Sell
660,034
-210,853
-24% -$11.3M 0.37% 70
2025
Q2
$44.8M Buy
870,887
+702
+0.1% +$35.3K 0.46% 46
2025
Q1
$51M Buy
870,185
+9,434
+1% +$639K 0.55% 27
2024
Q4
$62M Buy
860,751
+15,353
+2% +$1.13M 0.58% 28
2024
Q3
$67.6M Buy
845,398
+17,296
+2% +$1.3M 0.61% 22
2024
Q2
$59.3M Buy
828,102
+31,538
+4% +$2.32M 0.55% 28
2024
Q1
$56.1M Buy
796,564
+113,094
+17% +$8.09M 0.5% 34
2023
Q4
$52.7M Buy
683,470
+9,185
+1% +$605K 0.49% 41
2023
Q3
$45.9M Buy
674,285
+128,646
+24% +$10.2M 0.47% 47
2023
Q2
$44.5M Sell
545,639
-149,564
-22% -$12M 0.43% 49
2023
Q1
$51.6M Buy
695,203
+243,089
+54% +$18.7M 0.52% 36
2022
Q4
$37.5M Buy
452,114
+46,122
+11% +$3.66M 0.39% 54
2022
Q3
$28.8M Buy
405,992
+22,552
+6% +$1.95M 0.33% 70
2022
Q2
$33.2M Buy
383,440
+65,956
+21% +$6.18M 0.34% 66
2022
Q1
$34.4M Buy
317,484
+11,712
+4% +$1.21M 0.29% 74
2021
Q4
$39.5M Sell
305,772
-9,864
-3% -$1.21M 0.3% 69
2021
Q3
$38.2M Sell
315,636
-193,396
-38% -$23.5M 0.29% 74
2021
Q2
$57.3M Sell
509,032
-211,796
-29% -$22.3M 0.39% 42
2021
Q1
$68.8M Sell
720,828
-41,516
-5% -$3.79M 0.46% 30
2020
Q4
$60.5M Sell
762,344
-83,524
-10% -$6.05M 0.5% 33
2020
Q3
$52.4M Buy
845,868
+3,532
+0.4% +$230K 0.57% 25
2020
Q2
$55.6M Sell
842,336
-49,600
-6% -$2.97M 0.61% 22
2020
Q1
$42.3M Sell
891,936
-7,472
-0.8% -$374K 0.58% 34
2019
Q4
$49.4M Sell
899,408
-141,572
-14% -$7.43M 0.44% 51
2019
Q3
$50.9M Buy
1,040,980
+51,364
+5% +$2.58M 0.47% 48
2019
Q2
$51.6M Sell
989,616
-72,140
-7% -$3.64M 0.47% 47
2019
Q1
$52.7M Sell
1,061,756
-133,600
-11% -$6.01M 0.45% 51
2018
Q4
$43.2M Sell
1,195,356
-158,052
-12% -$6.6M 0.39% 55
2018
Q3
$69.1M Sell
1,353,408
-608,812
-31% -$27M 0.48% 37
2018
Q2
$72.6M Sell
1,962,220
-319,200
-14% -$12.2M 0.5% 36
2018
Q1
$86.1M Sell
2,281,420
-209,484
-8% -$7.4M 0.6% 24
2017
Q4
$80.7M Sell
2,490,904
-145,132
-6% -$4.61M 0.54% 32
2017
Q3
$79.7M Sell
2,636,036
-285,400
-10% -$8.47M 0.53% 33
2017
Q2
$85.8M Sell
2,921,436
-298,000
-9% -$8.15M 0.57% 29
2017
Q1
$81.8M Buy
3,219,436
+118,400
+4% +$3.06M 0.54% 29
2016
Q4
$79.7M Buy
3,101,036
+135,600
+5% +$3.56M 0.51% 33
2016
Q3
$81.2M Sell
2,965,436
-99,600
-3% -$2.74M 0.53% 29
2016
Q2
$86.4M Sell
3,065,036
-274,000
-8% -$7.04M 0.57% 25
2016
Q1
$78.9M Sell
3,339,036
-295,240
-8% -$6.5M 0.5% 31
2015
Q4
$81.8M Buy
3,634,276
+367,160
+11% +$8.37M 0.49% 36
2015
Q3
$75.5M Buy
3,267,116
+1,245,280
+62% +$31.2M 0.4% 53
2015
Q2
$49.8M Buy
2,021,836
+416,296
+26% +$10.4M 0.21% 124
2015
Q1
$40.3M Sell
1,605,540
-841,760
-34% -$20M 0.15% 174
2014
Q4
$56.5M Sell
2,447,300
-33,520
-1% -$767K 0.2% 138
2014
Q3
$58M Sell
2,480,820
-86,180
-3% -$2.02M 0.2% 131
2014
Q2
$59.4M Sell
2,567,000
-41,000
-2% -$906K 0.18% 143
2014
Q1
$55.7M Sell
2,608,000
-251,084
-9% -$5.65M 0.16% 156
2013
Q4
$67.7M Buy
2,859,084
+751,600
+36% +$16.3M 0.19% 141
2013
Q3
$42.2M Buy
2,107,484
+268,284
+15% +$5.09M 0.13% 210
2013
Q2
$31.8M Buy
+1,839,200
New +$30.5M 0.1% 257

Other funds holding TECH

Royce & Associates's TECH Position: Q1 2026 in Review

Royce & Associates increased its Bio-Techne (TECH) stake by 12% in Q1 2026, buying an estimated $4.87M and bringing the position to 759,712 shares worth $39.7M. The position accounts for 0.39% of the portfolio, ranked #59.

Royce & Associates first reported a position in TECH in Q2 2013 and has held it in 52 quarters since. The position peaked at $86.4M in Q2 2016. 582 funds tracked by Wall St. Rank hold TECH as of Q1 2026.

  • Royce & Associates held 759,712 shares of Bio-Techne worth $39.7M as of Q1 2026.
  • Royce & Associates bought 81,210 Bio-Techne shares in Q1 2026, an estimated $4.87M.
  • Bio-Techne made up 0.39% of Royce & Associates's portfolio in Q1 2026, its #59 holding.
  • Royce & Associates first reported a position in Bio-Techne in Q2 2013 and has held it in 52 quarters since.
  • Royce & Associates's Bio-Techne position peaked at $86.4M in Q2 2016.
  • 582 funds tracked by Wall St. Rank held Bio-Techne as of Q1 2026.

Based on Royce & Associates's 13F filing for Q1 2026, filed 12 May 2026.